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Summary
Background Tretinoin is considered the benchmark prescription topical therapy for
improving ﬁne facial wrinkles, but skin tolerance issues can affect patient compli-
ance. In contrast, cosmetic antiwrinkle products are well tolerated but are gener-
ally presumed to be less efﬁcacious than tretinoin.
Objectives To compare the efﬁcacy of a cosmetic moisturizer regimen vs. a pre-
scription regimen with 0Æ02% tretinoin for improving the appearance of facial
wrinkles.
Methods An 8-week, randomized, parallel-group study was conducted in 196
women with moderate to moderately severe periorbital wrinkles. Following
2 weeks washout, subjects on the cosmetic regimen (n = 99) used a sun protection
factor (SPF) 30 moisturizing lotion containing 5% niacinamide, peptides and
antioxidants, a moisturizing cream containing niacinamide and peptides, and a
targeted wrinkle product containing niacinamide, peptides and 0Æ3% retinyl propi-
onate. Subjects on the prescription regimen (n = 97) used 0Æ02% tretinoin plus
moisturizing SPF 30 sunscreen. Subject cohorts (n = 25) continued treatment for
an additional 16 weeks. Changes in facial wrinkling were assessed by both expert
grading and image analysis of digital images of subjects’ faces and by self-assess-
ment questionnaire. Product tolerance was assessed via clinical erythema and dry-
ness grading, subject self-assessment, and determinations of skin barrier integrity
(transepidermal water loss) and stratum corneum protein changes.
Results The cosmetic regimen signiﬁcantly improved wrinkle appearance after
8 weeks relative to tretinoin, with comparable beneﬁts after 24 weeks. The cos-
metic regimen was signiﬁcantly better tolerated than tretinoin through 8 weeks
by all measures.
Conclusions An appropriately designed cosmetic regimen can improve facial wrinkle
appearance comparably with the benchmark prescription treatment, with
improved tolerability.
Topical tretinoin is considered a benchmark treatment for the
mitigation of ﬁne facial wrinkles.
1–3 Use of tretinoin cream
(0Æ02%) has demonstrated a beneﬁt after 24 weeks of treat-
ment.
1 However, there are several side-effects (e.g. erythema
and desquamation) associated with tretinoin use, especially
during the ﬁrst few weeks, which may cause patients to dis-
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4 One study showed that concomitant use of a
niacinamide-containing moisturizer with tretinoin therapy
augmented the response to tretinoin and improved the stratum
corneum, decreasing tretinoin-associated side-effects.
5
In contrast to the irritancy potential of retinoid therapies,
cosmetic and cosmeceutical antiwrinkle products are generally
well tolerated by the skin and are pleasant for patients to use.
While there are few published reports of direct comparative
studies,
6 it is generally presumed that such products do not
have clinical efﬁcacy comparable with that of prescription top-
ical therapies such as tretinoin.
To determine whether signiﬁcant wrinkle reduction efﬁcacy
comparable with that of a prescription could be achieved
using cosmetic products, a treatment regimen was developed
containing niacinamide, the palmitoyl peptides palmitoyl-
lysine-threonine and palmitoyl-lysine-threonine-threonine-
lysine-serine (Pal-KT and Pal-KTTKS, respectively),
7–12 and a
less irritating retinyl ester commonly used in over-the-counter
and cosmetic products (retinyl propionate).
13,14 A study was
conducted to compare the efﬁcacy of this cosmetic niacin-
amide⁄peptide⁄retinyl propionate (NPP) product regimen vs.
a prescription 0Æ02% tretinoin product regimen for improving
the appearance of facial ﬁne lines and wrinkles. Product regi-
men tolerability was also assessed.
Materials and methods
Study design and subjects
An 8-week, randomized, parallel-group facial appearance
study was performed in Cincinnati, OH, U.S.A. from February
to August 2008 in 196 women aged 40–65 years who were
neither pregnant nor lactating. Eligible subjects had Fitzpatrick
skin types I–III and moderate to moderately severe periorbital
wrinkles on both sides of their face. Wrinkle severity was
assessed using a six-point ordinal photonumeric scale (Fig. 1).
Subjects preconditioned their face for 2 weeks using a mild
facial cleanser (Olay
  Foaming Face Wash; Procter & Gamble
Fig 1. Images illustrating the range of wrinkle
severity suitable for study inclusion. Severity
was graded on a 0–5 scale (at 0Æ5-grade
increments). Enrolled subjects had grades
between 3Æ5 and 4Æ5, inclusive, on each side
of their face. Images depicting the portion of
the scale including and bracketing the
acceptable grades are shown.
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turizer (Olay
  Complete All Day Moisture Lotion Sensitive
Skin SPF 15; Procter & Gamble Company) twice daily in place
of their regular cleansing and moisturizing products. After the
preconditioning period, subjects were randomly assigned to
either the NPP regimen or the tretinoin regimen for 8 weeks
of treatment. A computer-generated randomization list was
drawn up by the study statistician and was given to the study
site for treatment allocation. Prior to study start, 25 self-
selected subjects (cohort) on each product regimen agreed to
continue treatment for an additional 16 weeks. Written
informed consent for participation in this study was obtained
from all subjects in accordance with the Helsinki II declara-
tion, and the protocol was approved by an Institutional
Review Board (Schulman Associates IRB, Inc., Cincinnati, OH,
U.S.A.).
Study products
Subjects were instructed to dose both product regimens as per
the manufacturer’s package instructions or, when appropriate,
investigator guidance. Subjects assigned to the NPP regimen
used a daytime sun protection factor (SPF) 30 lotion (Olay
 
Professional Pro-X Age Repair Lotion SPF 30; Procter &
Gamble Company) in the morning, and a night cream (Olay
 
Professional Pro-X Wrinkle Smoothing Cream; Procter &
Gamble Company) in the evening, both over the entire face.
In addition, these subjects applied a wrinkle treatment (Olay
 
Professional Pro-X Deep Wrinkle Treatment; Procter & Gamble
Company) twice daily, that is, prior to the daytime SPF 30
lotion and the night cream, on areas of concern, as deter-
mined by the subject. Table 1 shows the ingredient list for the
test products. All the test products in the NPP regimen
contained niacinamide, the peptides Pal-KT and Pal-KTTKS, and
carnosine in a moisturizing base. The daytime SPF 30 lotion
also contained a broad-spectrum sunscreen (homosalate,
avobenzone, ensulizole, octocrylene) and vitamins C and E
(sodium ascorbyl phosphate and tocopheryl acetate). The wrin-
kle treatment contained 0Æ3% retinyl propionate. The subjects
randomized to the tretinoin regimen applied 0Æ02% tretinoin in
an emollient base (Renova
 ; Neutrogena Corporation, Los
Angeles, CA, U.S.A.)
15 to the entire face every other evening
and a manufacturer-recommended SPF 30 moisturizing
sunscreen (Neutrogena Healthy Defense
  Daily Moisturizer SPF
30; Johnson and Johnson) every morning for the ﬁrst 2 weeks;
after the initial 2-week period, subjects used the 0Æ02%
tretinoin every evening. Subjects of childbearing age in
the tretinoin regimen group had monthly urine pregnancy
tests during the study. To assess compliance, the products
were weighed at baseline and at each visit. Subjects and study
personnel dispensing product were not blinded to treatment.
Assessments
Improvement in the appearance of ﬁne lines and wrinkles was
measured by expert visual grading of high-resolution digital
images using the Rapid Evaluation of Anti-aging Leads (REAL
3.0) system
16 taken at baseline and at 8 and (in the cohort)
24 weeks. Three trained expert graders independently assessed
changes in the appearance of ﬁne lines and wrinkles around
the eyes by comparing identiﬁed baseline and post-treatment
images side-by-side using a ± eight-point ordinal scale. The
expert graders and other assessors were blinded to the treat-
ments. Dermatologists on the study advisory panel evaluated a
set of representative study images for concurrence with the
outcomes observed in expert grading. Images of the infraor-
bital⁄crow’s feet areas were also taken at baseline and at 8 and
24 weeks with the commercially available VISIA CR imaging
system (Canﬁeld Scientiﬁc, Fairﬁeld, NJ, U.S.A.) and analysed
for changes in periorbital wrinkle area fraction (wrinkle area
divided by assessment area).
In addition, each subject completed a self-assessment ques-
tionnaire containing 14 questions evaluating nine efﬁcacy
attributes (ﬁne lines and wrinkles around the eyes, evenness
of skin tone, red blotchiness, age spots, evenness of skin tex-
ture, skin ﬁrmness, skin radiance, skin hydration, and overall
appearance) using a 10-point continuous scale at baseline and
at 2, 4, 6 and 8 weeks in the entire study population and
additionally at 16 and 24 weeks in the cohort.
Subject tolerability to each regimen was measured by expert
clinical grading of erythema and dryness using a six-point
scale and by a subject self-assessment questionnaire using a
four-point scale at baseline and at 2, 4, 6 and 8 weeks in the
entire population and additionally at 16 and 24 weeks in the
cohort. Skin barrier integrity was measured by transepidermal
water loss (TEWL) at two sites on the face using a Vapometer
SWL-2 (Delﬁn Technologies, Ltd, Kuopio, Finland).
D-Squame
  tape strips (CuDerm Corporation, Dallas, TX,
U.S.A.) from the right cheek were collected at baseline and at
8 and 24 weeks, and analysed for the amount of soluble
protein, human serum albumin (HSA), involucrin, keratin 6,
keratins 1, 10 and 11, ﬁbronectin and cortisol via immuno-
assay (SkinMAP; Millipore, St Charles, MO, U.S.A.).
17 Levels
of keratin 6, ﬁbronectin and cortisol from over 90% of
the subjects were below detection limits; therefore, reliable
comparisons could not be made for these three analytes.
Table 1 Ingredients for niacinamide ⁄peptide ⁄retinyl propionate (NPP)
regimen products (in a moisturizing base)
Ingredient
Daytime
SPF 30 lotion
Night
cream
Wrinkle
treatment
Niacinamide X X X
Pal-KTTKS X X X
Pal-KT X X X
Carnosine X X X
Unique
ingredients
SPF 30,
vitamin C,
vitamin E
– Retinyl
propionate
Pal-KTTKS, palmitoyl-lysine-threonine-threonine-lysine-serine;
Pal-KT, palmitoyl-lysine-threonine; SPF, sun protection factor.
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The primary analysis variable was expert visual grading for the
change in appearance of ﬁne lines and wrinkles at 8 weeks.
For post-treatment analysis, expert visual grades for the change
in appearance of ﬁne lines and wrinkles, change from baseline
for wrinkle area fraction, erythema, dryness, self-assessment
efﬁcacy questions, and protein analytes from D-Squame
  tape
strips (normalized to total protein and log transformed) were
all analysed, separately, via an analysis of covariance model
with age and baseline wrinkle grade as covariates using SAS
version 9.1 software (SAS Institute, Cary, NC, U.S.A.). Self-
assessment tolerability questions were analysed using v
2 tests.
Results were considered signiﬁcant if P <0 Æ05 (two-sided).
Ninety-three subjects would permit detection of a mean wrin-
kle grade difference of 0Æ28 at 95% signiﬁcance (two-sided)
with an assumed SD of 0Æ95 and 80% power. Assuming a 5%
drop-out rate, 98 subjects for each group (196 in total) were
required.
Results
Subject accountability and baseline characteristics
Of the 97 tretinoin regimen subjects and 99 NPP regimen
subjects who started the study, 93 and 97 subjects, respec-
tively, completed the study. One subject in the tretinoin regi-
men group withdrew due to redness and dryness; three
subjects in the tretinoin regimen group and two in the NPP
regimen group were withdrawn due to noncompliance. Five
subjects (three in the tretinoin regimen group; two in the
NPP regimen group) were excluded from the REAL image
analysis due to image quality issues (facial expressions, etc.).
Table 2 shows the demographics and baseline values of the
two balanced groups.
Eight-week results
After 8 weeks of treatment, the appearance of facial ﬁne lines
and wrinkles improved in both groups as measured by expert
visual grading of the REAL images (P =0 Æ05, tretinoin regi-
men; P <0 Æ01, NPP regimen). The NPP regimen gave signiﬁ-
cantly greater improvement than the tretinoin regimen
(P <0 Æ01; Fig. 2). A signiﬁcantly higher percentage of sub-
jects on the NPP regimen (58%) was judged to look better
after 8 weeks of treatment, deﬁned as being given the mini-
mum positive grade of +1 on each side of their face by at
least two of the three graders, compared with the tretinoin
regimen (41%, P =0 Æ03). Also, a signiﬁcantly higher percent-
age of subjects on the NPP regimen responded substantially to
treatment (mean grade ‡ 2) as compared with the tretinoin
regimen (28% vs. 13%, P =0 Æ02). For perspective, a +2
grade would indicate visible improvement in at least one to
three small lines and⁄or 15–25% of areas of crepiness or
cross-hatching. Examples of subjects showing substantial
responses to each treatment regimen are shown in Figure 3.
As determined by analysis of the VISIA CR images, both
product regimens also signiﬁcantly reduced periorbital wrinkle
area fraction at week 8 relative to baseline (P <0 Æ01 for
both). The mean percentage reduction from baseline in wrin-
kle area fraction was greater for the NPP regimen group vs.
the tretinoin regimen group (17% vs. 11%, P =0 Æ06, Fig. 4).
Table 2 Demographics and baseline values of key parameters
Tretinoin regimen NPP regimen P-value
Age (years), mean ± SD (range) 53Æ1±6 Æ2 (40–65) (n = 97) 52Æ2±6 Æ2 (40–64) (n = 99) 0Æ05
Wrinkle area fraction (VISIA CR
image analysis), mean ± SEM
0Æ623 ± 0Æ019 (n = 93) 0Æ633 ± 0Æ019 (n = 97) 0Æ70
Erythema, mean ± SEM 0Æ972 ± 0Æ067 (n = 97) 0Æ929 ± 0Æ066 (n = 99) 0Æ65
Dryness, mean ± SEM 0Æ031 ± 0Æ016 (n = 97) 0Æ038 ± 0Æ016 (n = 99) 0Æ76
TEWL (g m
)2 h
)1), mean ± SEM 13Æ225 ± 0Æ335 (n = 95) 12Æ868 ± 0Æ328 (n = 99) 0Æ45
NPP, niacinamide ⁄peptide ⁄retinyl propionate; TEWL, transepidermal water loss.
Fig 2. Improvement in the appearance of periorbital wrinkles for the
full study population and 24-week cohort. Changes were determined
by expert visual comparison of subject images before and after
treatment, using a ± eight-point scale. Error bars represent SEM.
Entire population at 8 weeks: n = 90 in the tretinoin regimen group;
n = 95 in the niacinamide ⁄peptide ⁄retinyl propionate (NPP) regimen
group. Cohort at 8 weeks: n = 25 in each group. Cohort at 24 weeks:
n = 25 in the tretinoin regimen group; n = 23 in the NPP regimen
group.
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questions at 4 and 8 weeks is shown in Table 3. Both groups
noticed signiﬁcant improvement from baseline in overall skin
appearance, ﬁne lines and wrinkles, and eye lines and wrinkles
at both time points. After 4 weeks, subjects in the NPP
regimen group noticed a signiﬁcant improvement from base-
line in overall skin feel and uneven skin texture, and both
groups noticed a signiﬁcant improvement in these assessments
at 8 weeks. By 8 weeks, both groups noticed improvement
from baseline in deep wrinkles. The self-assessed improve-
ments in overall skin appearance, overall skin feel, and eye
lines and wrinkles were signiﬁcantly greater for the NPP regi-
(a)
(b)
Fig 3. (a) Niacinamide ⁄peptide ⁄retinyl
propionate regimen before and after 8 weeks
of treatment. (b) Tretinoin regimen before
and after 8 weeks of treatment.
Fig 4. Reductions in wrinkle area (as a fraction of the facial area of
interest) for the full study population and 24-week cohort. Wrinkle
area was determined by computer image analysis. Error bars indicate
95% conﬁdence interval. Entire population at 8 weeks: n = 92 in the
tretinoin regimen group; n = 95 in the niacinamide ⁄peptide ⁄retinyl
propionate (NPP) regimen group. Cohort at 8 weeks: n = 25 in the
tretinoin regimen group; n = 24 in the NPP regimen group. Cohort at
24 weeks: n = 25 in the tretinoin regimen group; n = 22 in the NPP
regimen group.
Table 3 Relevant efﬁcacy assessment questions from the self-
assessment questionnaire (change from baseline; full study
population)
Question
Week 4 Week 8
Tretinoin
regimen
NPP
regimen
Tretinoin
regimen
NPP
regimen
Overall skin appearance 0Æ287* 1Æ211*  1Æ296* 1Æ792* 
Overall skin feel )0Æ150 1Æ360*  0Æ759* 1Æ889* 
Fine lines ⁄wrinkles )0Æ625* )0Æ899* )1Æ110* )1Æ466*
Eye lines ⁄wrinkles )0Æ651* )1Æ206*  )1Æ337* )1Æ975* 
Deep wrinkles )0Æ233 )0Æ218 )0Æ562* )0Æ563*
Uneven skin texture 0Æ300 )0Æ528*  )0Æ506* )0Æ810*
NPP, niacinamide ⁄peptide ⁄retinyl propionate. *Statistically sig-
niﬁcantly different from baseline at P <0 Æ05.  Statistically sig-
niﬁcantly different from the tretinoin regimen at P <0 Æ05.
Attributes were graded by subjects on a 10-point continuous
scale at baseline and subsequent assessment periods. Changes in
grade were computed and compared, with positive numbers
meaning improvement for skin appearance and feel and negative
numbers (i.e. having less) representing improvement for the
other attributes.
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weeks, and for uneven skin texture after 4 weeks.
After 8 weeks of treatment, the stratum corneum barrier in
the tretinoin regimen group was signiﬁcantly compromised,
with TEWL increasing by 5Æ9gm
)2 h
)1 from baseline
(Fig. 5). TEWL values in the NPP regimen group remained es-
sentially unchanged from baseline. There was a signiﬁcant dif-
ference in change in TEWL between the two groups at
8 weeks (P <0 Æ01).
After 2 weeks of treatment, both product regimen groups
exhibited a signiﬁcant increase in erythema from baseline
(Fig. 6). After 4 weeks of treatment, erythema continued to
be signiﬁcantly increased in the tretinoin regimen group and
was signiﬁcantly higher compared with the NPP regimen
group (P =0 Æ01). Erythema in the NPP regimen group was
lower at 4, 6 and 8 weeks compared with 2 weeks and was
no longer statistically signiﬁcantly different from baseline. At
6 and 8 weeks, erythema did decrease in the tretinoin regi-
men but remained signiﬁcantly higher than at baseline.
At 2, 4, 6 and 8 weeks, the tretinoin regimen group
showed signiﬁcantly more skin dryness from baseline (Fig. 6).
There was no signiﬁcant change from baseline in skin dryness
in the NPP regimen group at 2, 4, 6 and 8 weeks. In addition,
the skin of subjects in the tretinoin regimen group was signiﬁ-
cantly drier than the skin of subjects in the NPP regimen
group at 2, 4, 6 and 8 weeks (P <0 Æ01 for all).
The results of the subjects’ self-assessments of product toler-
ability were consistent with the expert erythema and dryness
results (data not shown). Compared with the NPP regimen
group, after 2 weeks of treatment signiﬁcantly more subjects
in the tretinoin regimen group experienced itchiness, red-
ness⁄rash and peeling⁄ﬂaking, which is consistent with known
side-effects of tretinoin.
4 Symptoms continued in the tretinoin
regimen group for the entire 8-week study with a peak
between 4 and 6 weeks. Subjects in the NPP regimen group
who reported any irritation at any time point generally
reported experiencing it only a ‘slight amount’.
There were signiﬁcant differences between the product regi-
mens for each of the four stratum corneum protein analytes
after 8 weeks of treatment (Table 4). Soluble protein, HSA
and involucrin levels were signiﬁcantly increased from base-
line in the tretinoin regimen group. In contrast, in the NPP
regimen group, soluble protein and HSA decreased from base-
line, and involucrin was essentially unchanged from baseline.
Keratins 1, 10 and 11 signiﬁcantly decreased in the tretinoin
regimen group but were signiﬁcantly increased in the NPP
regimen group.
Cohort 24-week results
Of the 50 subjects (n = 25 in each group) who continued on
treatment for an additional 16 weeks, 48 (25, tretinoin regi-
men; 23, NPP regimen) completed the entire 24 weeks. As
seen in Figures 2 and 4, after 8 weeks treatment the mean
improvements in the two cohorts were not signiﬁcantly differ-
ent by either expert visual grading of the REAL images or by
image analysis of the VISIA CR images. The mean cohort
responses were not consistent with those determined in the
full study population, as the mean tretinoin response was
higher in the cohort than in the full population, while for the
Fig 5. Changes in facial skin transepidermal water loss (TEWL) for the
full study population and 24-week cohort. At 8 weeks, n = 91 for the
full population tretinoin group and n = 97 for the full population
niacinamide ⁄peptide ⁄retinyl propionate (NPP) regimen group; n =2 5
for both cohorts. At 24 weeks, n = 25 for the tretinoin regimen
cohort and n = 23 for the NPP regimen cohort.
Fig 6. Erythema and skin dryness during the
initial 8 weeks of treatment (full study
population). Both erythema and clinical
dryness were determined on a 0–6 scale. For
the tretinoin regimen, n = 95 (week 2),
n = 94 (week 4) and n = 93 (weeks 6 and
8). For the niacinamide ⁄peptide ⁄retinyl
propionate (NPP) regimen, n = 99 (week 2)
and n = 97 (weeks 4, 6 and 8).
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attributable to the self-selection of the cohort subjects, which
was made prior to the start of treatment. Wrinkle severity at
enrolment, however, was not signiﬁcantly different between
the cohorts, nor was it signiﬁcantly different between the
cohorts and the full populations. For both regimens, the
appearance of facial ﬁne lines and wrinkles continued
to improve from 8 to 24 weeks as measured by both visual
grading and image analysis (P <0 Æ01 for both). Consistent
with the 8-week results for the cohort, after 24 weeks of treat-
ment there were no signiﬁcant differences between the NPP reg-
imen and the tretinoin regimen by either measure (P =0 Æ74,
P =0 Æ77, respectively). There was a statistically signiﬁcant dif-
ference in change in TEWL between the two groups at 8 and
24 weeks (P <0 Æ01, Fig. 5). After 24 weeks of treatment, the
stratum corneum barrier was not different from baseline in the
tretinoin regimen group (P =0 Æ47) but was signiﬁcantly
improved in the NPP regimen group (P <0 Æ01).
After 16 and 24 weeks of treatment, the subset of the NPP
regimen group exhibited a nonsigniﬁcant decrease from base-
line in erythema and dryness (P >0 Æ21, data not shown).
After 16 weeks of treatment, erythema in the subset of the
tretinoin regimen group was not different from baseline, but
at 24 weeks of treatment there was a signiﬁcant decrease in
erythema. Skin dryness in the tretinoin regimen cohort was
not signiﬁcantly different from baseline after 16 and 24 weeks
of treatment.
In general, subjects in both groups continued to notice an
improvement in their skin from baseline based on the self-
assessment questionnaire (data not shown). In addition, the
NPP regimen subjects did not report any signiﬁcant irritation
after 16 and 24 weeks of treatment; the tretinoin regimen
subjects did report signiﬁcant peeling and ﬂaking at 16 weeks
but no signiﬁcant irritation after 24 weeks (data not shown).
After 8 weeks, protein analyte changes in the cohort were
consistent with those in the full population (Table 4). After
24 weeks, protein changes in both cohorts generally improved
relative to 8 weeks. None the less, soluble protein levels
remained signiﬁcantly higher than baseline in the tretinoin
regimen group and signiﬁcantly lower than baseline in the
NPP regimen group. Levels of HSA were similar to baseline in
the tretinoin regimen group (P =0 Æ59) but signiﬁcantly
reduced relative to baseline in the NPP regimen group. Involu-
crin levels remained not signiﬁcantly different from baseline
following 24 weeks use of the NPP regimen; however, levels
of involucrin in the tretinoin regimen group decreased
between 8 and 24 weeks, which is consistent with the TEWL
and irritation data showing accommodation to tretinoin
treatment with longer term use. Overall, the NPP regimen
group had signiﬁcantly lower levels of soluble protein, HSA
and involucrin and signiﬁcantly higher levels of keratins 1, 10
and 11 than the tretinoin regimen group at 24 weeks.
Discussion
To our knowledge, this is the ﬁrst of its kind long-term clini-
cal study comparing a cosmetic anti-ageing regimen against a
recognized prescription topical treatment for improving the
appearance of facial wrinkling. The NPP regimen, which con-
tained cosmetic ingredients known to affect the appearance of
wrinkles, along with moisturizing and skin barrier building
components, comparably improved the appearance of ﬁne
lines and wrinkles relative to the prescription tretinoin regi-
men as measured by both expert grading and image analysis
in a long-term study, with better tolerability. Improvements
in skin texture with topical niacinamide treatment have been
reported and linked to enhanced barrier function,
7 and a pep-
tide used in the NPP regimen has been shown to reduce the
appearance of ﬁne lines and wrinkles without adverse effects
on skin barrier.
10 The beneﬁcial impact of the NPP regimen
ingredients is consistent with the results seen for TEWL, pro-
tein analyte changes, and the clinical data on erythema and
dryness. Multiple studies have established the beneﬁcial effects
of niacinamide for improving barrier function of the stratum
corneum as measured by TEWL.
18–20 In the present investiga-
tion the NPP regimen had less of a positive effect on TEWL at
8 weeks vs. baseline than one would expect from the literature
given that all three products contained niacinamide. The
muted beneﬁt on TEWL was probably a consequence of the
wrinkle treatment product also containing retinyl propionate.
Table 4 Changes in stratum corneum protein analytes
Percentage change from baseline
week 8 (entire population)
Percentage change from baseline
week 8 (cohorts)
Percentage change from baseline
week 24 (cohorts)
Tretinoin
regimen
NPP
regimen P-value
Tretinoin
regimen
NPP
regimen P-value
Tretinoin
regimen
NPP
regimen P-value
Soluble protein (lgm L
)1) 140Æ44* )9Æ43 < 0Æ01 160Æ62* )1Æ83* < 0Æ01 72Æ98* )43Æ64* < 0Æ01
HSA (ng mL
)1)5 2 Æ41* )33Æ01* < 0Æ01 62Æ55* )39Æ74* < 0Æ01 )9Æ43 )73Æ39* < 0Æ01
Involucrin
(ng lg
)1 soluble protein)
115Æ28* 0Æ46 < 0Æ01 155Æ27* 4Æ95 < 0Æ01 51Æ71 )31Æ61 < 0Æ05
Keratins 1, 10 and 11
(ng lg
)1 soluble protein)
)58Æ79* 27Æ06* < 0Æ01 )62Æ07* 18Æ30 < 0Æ01 )7Æ74 179Æ90* < 0Æ01
HSA, human serum albumin; NPP, niacinamide ⁄peptide ⁄retinyl propionate. *Signiﬁcantly different from baseline at P <0 Æ05. Listed P-values
are for treatment comparisons.
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stabilization of stratum corneum repair mechanisms may occur
at different rates, as TEWL values in the tretinoin cohort had
returned to baseline by week 24 but some marker protein lev-
els had not.
We recognize that there are limitations in this study. Treti-
noin is more irritating to the skin and the products tested in
the NPP regimen are more moisturizing. Additionally, while
the evaluators were blinded to treatment, the subjects were
not which could have affected the subjects’ self-assessments.
Finally, a larger 24-week cohort group size would have pro-
vided more statistical power for more robust conclusions.
These limitations notwithstanding, the study data, from both
objective and subjective assessments, provided consistent
results and showed that the new NPP regimen improved the
appearance of ﬁne lines and wrinkles similarly to the tretinoin
regimen, with fewer side-effects.
The results of this study show that the efﬁcacy of a pre-
scription product for improving the appearance of facial ﬁne
lines and wrinkles can be achieved with an appropriately
designed cosmetic regimen, while providing additional
beneﬁts in aesthetics, skin tolerance and potential patient
compliance.
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